MUDr. Petra Prvni s.r.o.
- Address
- lock Available on a paid plan
Digestive System Diseases
The trial assesses how Saccharomyces boulardii influences gut microbiota in patients receiving antibiotic therapy for erythema migrans, the early skin manifestation of Lyme borreliosis.
- Probiotic modulation of the microbiome
- Prevention of antibiotic‑associated dysbiosis
- Supportive care in early Lyme disease
MUDr. Petra Prvni s.r.o. in Radomysl is conducting this research to improve outcomes for patients undergoing treatment for tick‑borne infections while preserving digestive health.
Virus Diseases
The study compares the efficacy of ibuzatrelvir with placebo in non‑hospitalized COVID‑19 patients who are at high risk of severe illness, aiming to reduce disease progression.
- Evaluation of oral antiviral agents
- Outpatient management strategies for COVID‑19
- Risk stratification for severe viral disease
At MUDr. Petra Prvni s.r.o., researchers are focused on advancing therapeutic options that can keep high‑risk individuals out of the hospital and lessen the impact of the pandemic.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Biocodex1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MUDr. Petra Prvni s.r.o.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Saccharomyces boulardii CNCM I-745 and Amoxicillin on Gut Microbiota in Patients with Erythema Migrans Undergoing Antibiotic Therapy | Biocodex | Phase III | Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amoxicillin | 1 | Unknown | 2024-06-18 | 2024-06-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.